Table 2.

Embryogenesis: Intention to Treat

		Number of Living Female Worms
			Embryogenesis
Treatment	Number of Patients/Nodules	All	Judgement Not Possiblea	Uterus Empty	Oocytes Only	Degenerated Embryogenesis Only	Normal Embryogenesisb,c
IVM annual	54/155	151	16	34	75	11 (8.1% [5–14])	15 (11.1% [7–18])
IVM semiannual	55/165	182	27	32	81	20 (12.9% [9–19])	22 (14.2% [10–21])
IVM + ALB annual	59/157	171	17	34	66	19 (12.3% [8–18])	35 (22.7% [17–30])
IVM + ALB semiannual	48/140	142d	17	30	63	11 (8.8% [5–15])	20 (16% [11–23])
All	216/617e	646	77	130	286	61 (10.7% [8; 14])	92 (16.2% [13; 19])

Data are given as n (% [95% confidence interval]).

Abbreviations: ALB, albendazole; IVM, ivermectin.

^aIn 77 out of the 646 live female worms, the judgement of the embryogenesis was not possible: for example, due to bad quality of the slide, the uterus not being truncated, indefinable contents of the uterus, or folded worm sections.

^b95% confidence intervals for proportions were calculated using the recommended method by Altman et al [30].

^cComparison of all groups (live female worms with normal embryogenesis vs all other live female worms with evaluated embryogenesis): P = .1229 (Proc Genmod, SAS).

^dIn 1 live female worm, judgement of embryogenesis was possible but could not be assigned to 1 of the embyrogenic stages, as the worm was neoplastic. Therefore, the described stages sum up to 141 instead of 142. The worm has been analyzed as a worm with no normal embryogenesis.

^eThe nodules from 2 out of 218 patients could not be analyzed, because no oncho nodules or no worm section could be found (IVM + ALB semiannual n = 2); 60 nodules out of 677 nodules analyzed were not evaluable (IVM annual n = 8, IVM semiannual n = 14, IVM + ALB annual n = 22, IVM + ALB semiannual n = 16).